GLP-1 receptor agonists — the drug class that includes semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) — have become among the most discussed medications in the country. Their dramatic effects on appetite, weight and blood sugar have made them the subject of enormous cultural attention, and that attention has generated a predictable set of questions about misuse.
Can these drugs be abused? Are people misusing them for weight loss beyond their prescribed indications? And separately — a question with significant implications for addiction medicine — is there evidence they might actually help people struggling with substance use disorders?
This article addresses both questions in order because they point in opposite directions: The first is about whether GLP-1s carry addiction or misuse risk, and the second is about whether they may represent a genuinely new pharmacological tool for treating addiction in others.
What GLP-1 Receptor Agonists Are and How They Work
Glucagon-like peptide-1 (GLP-1) is a hormone produced naturally in the gut and brain stem in response to food intake. It stimulates insulin secretion, suppresses glucagon release, slows gastric emptying and signals satiety to the brain. GLP-1 receptor agonists are synthetic molecules that mimic or enhance this hormone’s activity at its receptors.
The first GLP-1 receptor agonist, exenatide (Byetta), was approved in 2005 for type 2 diabetes. It was derived, improbably, from a compound found in the saliva of the Gila monster. Semaglutide, approved in 2017 and administered once weekly, improved significantly on its predecessors in potency and convenience. The FDA approved a higher-dose formulation, Wegovy, for chronic weight management in 2021, and the category has been expanding rapidly since. Tirzepatide, a dual GLP-1 and GIP receptor agonist, was approved for obesity in 2023 and has demonstrated even larger effects on body weight than semaglutide alone.
GLP-1 receptors are present not only in the pancreas and gut but also in the brain — including in regions associated with reward processing, motivation and compulsive behavior. This neurological distribution is central to understanding both the misuse question and the addiction treatment question.
Can GLP-1s Be Abused?
The short answer is: not in the classical pharmacological sense. GLP-1 receptor agonists don’t produce euphoria, don’t act on dopamine reward pathways in a way that generates compulsive drug-seeking and aren’t associated with physical dependence or withdrawal syndromes. They carry no DEA scheduling and aren’t classified as controlled substances. By the standard pharmacological definition of abuse potential — the capacity to produce reinforcing subjective effects that drive compulsive use — GLP-1s don’t qualify.
What does exist is a pattern of misuse in the broader sense: people obtaining and using GLP-1 medications outside their approved indications, without medical supervision, primarily for weight loss. This includes people who don’t meet the clinical criteria for obesity or who obtain the drugs through compounding pharmacies, telehealth platforms with minimal screening or informal channels. The FDA has issued warnings about counterfeit semaglutide products circulating in the market, and reports of adverse events from unverified sources have increased alongside the drugs’ popularity.
The Body Dysmorphia Concern
The more clinically significant misuse concern is the intersection of GLP-1 use with eating disorders and body dysmorphia. People with restrictive eating disorders — anorexia nervosa in particular — represent a population for whom appetite suppression carries real risk of harm. GLP-1s are contraindicated in people with a history of eating disorders, but that contraindication depends on accurate disclosure during prescribing. The cultural normalization of GLP-1 use for weight loss, combined with the relative ease of access through telehealth, has raised concern among eating disorder specialists about medications reaching people for whom they’re inappropriate and potentially dangerous.
Muscle Loss and Unsupervised Use
GLP-1s used without concurrent medical supervision and adequate protein intake can contribute to significant lean muscle mass loss alongside fat loss — a phenomenon sometimes referred to informally as Ozempic body. Rapid weight loss without appropriate nutritional support also carries risks for bone density and metabolic function. These are harms associated with unsupervised use rather than the pharmacology of the drugs themselves, but they’re clinically meaningful risks in the current prescribing landscape.
Psychological Dependence on the Effect
There’s emerging clinical observation — not yet well-characterized in the literature — of patients developing significant anxiety around discontinuation of GLP-1 medications, due not to physical withdrawal (which doesn’t occur) but to fear of weight regain. Studies have consistently shown that weight loss achieved with GLP-1 medications is largely reversed upon discontinuation, which creates a dynamic in which continued use feels medically necessary. This is a prescribing and access question as much as a pharmacological one, but it’s worth distinguishing from the classical definition of dependence.
GLP-1s and the Brain’s Reward System
The more scientifically significant story about GLP-1s and addiction runs in the opposite direction from misuse. A growing body of preclinical and clinical research suggests GLP-1 receptor agonists may reduce craving and consumption across a remarkably broad range of addictive substances and behaviors.
GLP-1 receptors are expressed in the nucleus accumbens, the ventral tegmental area and the prefrontal cortex — brain regions that constitute the mesolimbic dopamine system, the primary neurological base of addiction. Activation of GLP-1 receptors in these regions appears to dampen the release of dopamine in response to rewarding stimuli, reducing the subjective prominence of those stimuli. In animal models, this effect has been demonstrated across alcohol, opioids, cocaine, amphetamines and nicotine.
Clinicians treating patients with GLP-1 medications for weight and metabolic conditions began reporting, anecdotally, that patients were spontaneously reducing or stopping alcohol use, smoking and other compulsive behaviors. These observations prompted researchers to examine the phenomenon more systematically.
What the Research Shows
Alcohol Use Disorder
The most developed clinical evidence involves alcohol use disorder (AUD). A 2025 randomized controlled trial published in JAMA Psychiatry by Hendershot and colleagues at the University of North Carolina evaluated once-weekly semaglutide in 48 adults with AUD over 9 weeks. Relative to placebo, semaglutide significantly reduced the number of drinks per drinking day, weekly alcohol craving and the total amount of alcohol consumed in a laboratory self-administration procedure. Effect sizes were in the medium-to-large range. The trial was small, but its design was rigorous, and its findings have generated substantial interest in the research community, with larger Phase 3 trials now underway.
Observational data support these findings at scale. A 2024 analysis of nearly 600,000 patients with diabetes found those treated with semaglutide had a 50% to 56% lower risk of new or recurring alcohol use disorder compared to patients on other diabetes medications. A separate cohort study of more than 227,000 individuals with AUD found that semaglutide and liraglutide were associated with lower rates of alcohol-related hospitalization than established AUD medications including acamprosate, disulfiram and naltrexone. These are observational findings and carry the limitations of that study design, but they’re consistent with the mechanistic hypothesis and the RCT data.
Opioid Use Disorder
Preclinical data from rodent models show that GLP-1 receptor agonists reduce self-administration of heroin, fentanyl and oxycodone, and attenuate reinstatement of drug-seeking — a validated model of relapse. Human data are more limited at this stage. A 2024 retrospective analysis of approximately 33,000 medical records found that patients with type 2 diabetes treated with semaglutide had roughly one-third to one-half the risk of opioid overdose compared to patients on other diabetes medications — a finding that, while preliminary, has significant implications given the scale of the opioid crisis.
Stimulants, Nicotine and Behavioral Addictions
Preclinical evidence extends to cocaine, amphetamines and nicotine, with GLP-1 receptor agonists consistently reducing self-administration and reinstatement across these substances in animal models. The JAMA Psychiatry AUD trial also observed reductions in cigarette consumption in the subgroup of participants who smoked, a secondary finding that adds to the nicotine signal. Reports of reduced compulsive behaviors including gambling and hypersexuality have emerged from clinical observation, though these remain anecdotal at this stage.
The breadth of the effect across substance classes and behavioral compulsions is notable and has led some researchers to hypothesize that GLP-1 receptor agonists may be targeting something fundamental about the neurobiology of craving and reward prominence, rather than acting on any substance-specific mechanism.
Important Limitations and What We Don’t Yet Know
The research, while promising, is early. The pivotal AUD trial enrolled 48 participants. Most of the opioid and stimulant evidence comes from animal models, which don’t always translate reliably to human clinical outcomes. The observational studies, while large, are subject to confounding — patients prescribed semaglutide may differ systematically from comparison groups in ways that explain some of the observed benefit.
There are also practical concerns. GLP-1 medications are expensive — list prices for semaglutide run to $1,000 or more per month without insurance coverage, and coverage for addiction indications doesn’t currently exist. Side effects, which include significant nausea, vomiting and gastrointestinal distress, particularly during dose escalation, affect tolerability and adherence. The appropriate dose, duration and patient selection criteria for addiction applications remain unknown and are subjects of active investigation.
One concern specific to the addiction context deserves attention. Some researchers have noted that GLP-1 medications may reduce motivation and hedonic tone more broadly — a flattening of reward-seeking behavior that could be beneficial in addiction but potentially problematic in patients with depression or anhedonia. Monitoring for mood effects in this population will be important in future trials.
Where This Fits in the Current Treatment Landscape
GLP-1 receptor agonists aren’t currently FDA-approved for any substance use disorder indication. They shouldn’t be sought out or used as self-directed addiction treatment, and their use for this purpose outside of a clinical trial or formal medical supervision isn’t appropriate given the current state of evidence.
What the research represents is a credible and rapidly developing signal that warrants serious investigation. The existing pharmacological toolkit for addiction is limited: FDA-approved medications exist for opioid use disorder (buprenorphine, methadone, naltrexone) and alcohol use disorder (naltrexone, acamprosate, disulfiram), but no approved medications exist for stimulant use disorders, and treatment engagement and retention remain challenges across all substance classes. A medication that appears to reduce craving across multiple substances through a shared mechanism would be a significant advance.
Phase 3 trials are currently underway or in development for semaglutide in alcohol use disorder. The next several years will produce substantially clearer evidence about whether the early findings hold at scale. If they do, GLP-1 receptor agonists may become part of the standard treatment resources for addiction medicine within the decade.
For anyone currently struggling with substance use disorder, the most effective available treatments remain evidence-based behavioral therapy, FDA-approved medications where applicable and structured levels of care ranging from outpatient programs to residential treatment. The National Rehab Hotline can help identify appropriate treatment based on your specific situation, substance use history and insurance coverage. The service is free and available 24 hours a day.
